• Quick and reliable gender determination of chicken embryos in the egg
• New technology means poultry farming industry can avoid killing of male chicks
• Strengthening of Evonik’s Animal Nutrition growth engine through expansion in egg-producing sector
Evonik has invested in the biotechnology start-up In Ovo through its venture capital unit and now holds a minority stake in the company, based in Leiden (the Netherlands). Co-leading this Series A investment is Singapore-based venture capital fund, VisVires New Protein. Along with the participation of Leiden University this brings the total financing round to an investment of several million.
“In Ovo has taken on one of the biggest ethical problems in modern poultry farming,” says Bernhard Mohr, head of Venture Capital at Evonik. “This investment strengthens Evonik’s position as a partner of choice for the farming industry as we can provide support for ethical food production.”
In Germany alone, an estimated 40 million day-old male chicks from laying-hen hatcheries are killed annually, and the global figure is thought to be 3.2 billion. Poultry farms don’t rear the male animals because they can neither lay eggs nor put on sufficient flesh for meat production.
In Ovo has developed a method for determining the sex in the egg that is particularly fast and reliable and can be readily integrated into the workflow of large hatcheries. The technology is being combined with a system to process the large number of eggs to be screened. In large hatcheries about 100,000 eggs must be analyzed daily.
“In Ovo is an excellent strategic fit for Evonik’s existing business,” says Emmanuel Auer, head of the company’s Animal Nutrition business line. “This commitment will sustainably strengthen our Animal Nutrition growth engine by allowing us to expand our presence in the egg-producing sector.”
Evonik products and services in the field of animal nutrition play a key role worldwide in the production of healthy and affordable food with conservation of natural resources and a reduced ecological footprint. The company is a leading global supplier of amino acids and their derivatives for advanced animal nutrition and is systematically expanding its product range in the direction of sustainable and healthy animal nutrition.
In Ovo was founded in 2013 by biomedical scientist Wil Stutterheim and biologist Wouter Bruins, who met at the University of Leiden. The technology is based on biomarkers identified by the founders; these allow the gender of chick embryos in the egg to be accurately determined early after fertilization. For this purpose a tiny, easily resealable hole is made in the egg—this has for many years been standard procedure for inoculation of chick embryos in the egg. A sample is then taken and examined by mass spectrometry for the biomarker identified by In Ovo, which has already been patented. In Ovo plans to use the invested capital to develop the technology to the stage where it can be applied on the commercial scale in hatcheries.
“In Evonik, we’re delighted to have gained a partner with extensive knowledge of process scale-up and in the introduction of new technologies,” says Wouter Bruins, co-founder and one of the managing directors of In Ovo.
Over the next few months the founders plan to work with German and Dutch partners to develop a prototype that can rapidly and reliably analyze and sort large quantities of eggs. On the laboratory scale, In Ovo currently needs one second for the analysis of an egg. This rate is now to be accelerated to a few microseconds per egg. The company will also use already available and proven technologies for sorting and handling large quantities of eggs. The first commercial product is expected to be launched on the market in 2020.
As part of its venture capital activities Evonik plans to invest a total of €100 million in promising start-ups with innovative technologies and in leading specialized venture capital funds. The focus here is on Evonik’s Health & Care, Smart Materials, Animal Nutrition, and Specialty Additives growth engines as well as on digitalization. Evonik currently has investments in more than twenty start-ups and venture capital funds. Further information is available at http://venturing.evonik.com/
Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-orientated innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik’s corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world with more than 36,000 employees. In fiscal 2017, the enterprise generated sales of €14.4 billion and an operating profit (adjusted EBITDA) of €2.36 billion.
Evonik’s international activities are organized into six regions. The Asia Pacific North region is headquartered in Shanghai. Sales in Asia Pacific North reached 2,158 million euros in 2017. Evonik regards China as one of the driving forces of the global economy and we consequently endeavor to grow our business here. The company now employs about 3,000 employees and has in total of 10 production sites in China.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.